Join the Fight Against MDS
Every gift helps patients, caregivers, and healthcare professionals access life-saving resources, support, and education. Together, we can make a difference. Even a small contribution can create a big impact. Thank you for your generosity.
August 7, 2021
Outcomes for High-Risk MDS Patients Undergoing Transplant vs Standard Non-Transplant Therapies
Outcomes for High-Risk MDS Patients Undergoing Transplant vs Standard Non-Transplant Therapies
This webinar will provide an overview of the role of allogeneic hematopoietic cell transplantation (alloHCT) for high-risk MDS patients. Standard therapies for patients with MDS including hypomethylating agents (HMAs) and a variety of novel agents outside of allogeneic HCT will be discussed.
Speaker
Erica D. Warlick, MD
Outputs
Access to the meeting outputs are available below by clicking on each topic.
Our Supporters
Thank you to Bristol-Myers Squibb, Novartis, Jazz Pharmaceuticals, Takeda Oncology, Acceleron, and Gamida Cell for supporting this initiative.
